Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Public ClinicalTrials.gov record NCT04340596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Study identification
- NCT ID
- NCT04340596
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 118 participants
Conditions and interventions
Conditions
Interventions
- N-803 (IL-15 Superagonist) Biological
- VRC07-523LS Biological
- 10-1074 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2021 (Actual)
- Primary completion
- May 7, 2026 (Actual)
- Completion
- Dec 30, 2026 (Estimated)
- Last update posted
- Aug 26, 2026
2021 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama CRS (Site ID# 31788) | Birmingham | Alabama | 35222 | — |
| UCLA CARE Center CRS | Los Angeles | California | 90035 | — |
| UCSD Antiviral Research Center CRS (Site ID: 701) | San Diego | California | 92103 | — |
| University of California, San Fransisco HIV/AIDS CRS | San Francisco | California | 94110 | — |
| Whitman-Walker Institute, Inc. CRS (Site ID: 31791) | Washington D.C. | District of Columbia | 20005 | — |
| Northwestern University CRS | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101) | Boston | Massachusetts | 02114 | — |
| Washington University Therapeutics (WT) CRS | St Louis | Missouri | 63110-1010 | — |
| New Jersey Medical School Clinical Research Center CRS [Site ID: 31786] | Newark | New Jersey | 07103 | — |
| Columbia P&S CRS | New York | New York | 10032 | — |
| Weill Cornell Uptown CRS (Site ID: 7803) | New York | New York | 10065 | — |
| Chapel Hill CRS (Site ID: 3201) | Chapel Hill | North Carolina | 27599 | — |
| Case Clinical Research Site | Cleveland | Ohio | 44106 | — |
| Penn Therapeutics, CRS (Site ID: 6201) | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04340596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04340596 live on ClinicalTrials.gov.